IP Library Granted Patent US 11,317,957
Granted Patent B2
US 11,317,957 · App. 16/637,363 · Granted May 3, 2022

Fiber reinforced biocomposite threaded implants

Inventors: Orahn Preiss-Bloom (Caesarea, IL); Taly Pnina Lindner (Caesarea, IL); Ilan Oleg Uchitel (Caesarea, IL); Ilya Krivoruk (Caesarea, IL)
Assignee: OSSIO, LTD.
A61B17/866A61B17/863A61L31/128A61L31/148B29C70/081B29C70/86A61B17/864B29K2267/043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,317,957
App. No.
16/637,363
Granted
May 3, 2022
Kind
B2
Abstract

A threaded medical implant comprising a biocomposite, said biocomposite comprising a polymer and a plurality of reinforcement fibers, wherein a weight percentage of a mineral composition within the biocomposite medical implant is in the range of 30-60%, wherein an average diameter of said fibers is in a range of 1-100 microns, said medical implant being threaded with a plurality of threads; wherein said fibers comprise a plurality of helical fibers and a plurality of longitudinal fibers; wherein a weight to weight percent ratio of said helical to said longitudinal fibers is from 90:10 to 10:90.

Claims (31)

1. A medical implant comprising a biocomposite, said biocomposite comprising a polymer and a plurality of reinforcement fibers, wherein a weight percentage of a mineral composition within the biocomposite medical implant is in a range of 30-60%, wherein an average diameter of said fibers is in a range of 1-100 microns, said medical implant being threaded with a plurality of threads; wherein said fibers comprise a plurality of helical fibers and a plurality of longitudinal fibers; wherein a weight percentage to weight percentage ratio of said helical to said longitudinal fibers is from 90:10 to 10:90.

2. The implant of claim 1 , wherein a winding angle of said helical layers is in a range of from 5 to 60 degrees or from 20 degrees to 45 degrees.

3. The implant of claim 1 wherein the implant threads are of a constant pitch or of a variable pitch.

4. The implant of claim 1 , wherein said biocomposite is arranged in a plurality of layers, wherein fibers in each layer are discontinuous to an adjacent layer.

5. The implant of claim 4 , wherein helical fibers in a first layer are wound clockwise while helical fibers in an adjacent layer are wound counterclockwise.

6. The implant of claim 5 , wherein a winding angle of said helical fibers is wound toward an area of greater torsional stress of the implant.

7. The implant of claim 4 , further comprising a plurality of helical layers and a plurality of longitudinal layers, wherein said helical and longitudinal layers are each grouped into discrete regions of wall thickness of the implant such that they form concentric regions in the implant.

8. The implant of claim 7 , wherein a number of helical layers is in a range of from 1 to 15, preferably in the range of 1 to 10, more preferably in the range of 4 to 6, or optionally in the range of 8 to 15.

9. The implant of claim 8 , wherein a diameter of the threaded implant is in the range of 2 to 4 mm and the number of helical layers is in the range of 2-12, preferably 3-8.

10. The implant of claim 8 , wherein a number of longitudinal layers is in a range of from 1 to 15, preferably in the range of 1 to 10, more preferably in the range of 4-6, or optionally in the range of 1-5.

11. The implant of claim 1 further comprising at least one layer of a plurality of layers comprising a plurality of continuous fibers along said layer, and at least one other layer comprising a plurality of chopped fibers, wherein a length of said chopped fibers is less than a length of said at least one other layer.

12. The implant of claim 11 , wherein an average length of the chopped fibers is <10% of the length of the implant and preferably <5% of the length of the implant.

13. The implant of claim 11 , wherein of threads, and wherein said chopped fibers are located at said plurality of threads for reinforcement.

14. The implant of claim 1 , wherein the plurality of threads form a single set of threads.

15. The implant of claim 1 , comprising multiple sets of threads.

16. The implant of claim 1 , comprising threads having a fixed lead or progressive lead.

17. The implant of claim 1 , comprising threads having a fixed pitch or progressive pitch.

18. The implant of claim 1 , wherein threading is not continuous throughout the circumference.

19. The implant of claim 1 , wherein said plurality of threads comprise a shape selected from the group consisting of V thread, buttress, reverse buttress, spiral, combination of buttress and reverse, trapezoidal, square or a combination thereof.

20. The implant of claim 1 wherein an average depth of the threads is in the range of 0.2-4 mm.

21. The implant of claim 1 further comprising one or more longitudinal grooves breaking in the threads.

22. The implant of claim 21 , wherein said one or more longitudinal grooves span an entire length of the plurality of threads.

23. The implant of claim 21 , wherein said one or more longitudinal grooves span up to 80% of an entire length of the plurality of threads.

24. The implant of claim 1 , wherein said mineral composition is silica-based.

25. The implant of claim 1 , wherein density of the biocomposite composition is between 0.5 to 4 g/cm 3 , between 1 to 3 g/cm 3 , or between 1.3-2.5 g/cm 3 .

26. The implant of claim 1 , wherein mineral content is provided by a reinforcing mineral fiber made from the mineral composition.

27. The implant of claim 26 , wherein said fibers are embedded in a polymer matrix comprising said biocomposite.

28. The implant of claim 27 , wherein said polymer comprises lactide, glycolide, caprolactone, valerolactone, carbonates (e.g., trimethylene carbonate, tetramethylene carbonate, and the like), dioxanones (e.g., 1,4-dioxanone), δ-valerolactone, 1, dioxepanones e.g., 1,4-dioxepan-2-one and 1,5-dioxepan-2-one), ethylene glycol, ethylene oxide, esteramides, γ-ydroxyvalerate, β-hydroxypropionate, alpha-hydroxy acid, hydroxybuterates, poly (ortho esters), hydroxy alkanoates, tyrosine carbonates, polyimide carbonates, polyimino carbonates such as poly (bisphenol A-iminocarbonate) and poly (hydroquinone-iminocarbonate, (polyurethanes, polyanhydrides, polymer drugs (e.g., polydiflunisol, polyaspirin, and protein therapeutics), sugars; starch, cellulose and cellulose derivatives, polysaccharides, collagen, chitosan, fibrin, hyaluronic acid, polypeptides, proteins, poly (amino acids), polylactides (PLA), poly-L-lactide (PLLA), poly-DL-lactide (PDLLA); polyglycolide (PGA); copolymers of glycolide, glycolide/trimethylene carbonate copolymers (PGA/TMC); other copolymers of PLA, such as lactide/tetramethylglycolide copolymers, lactide/trimethylene carbonate copolymers, lactide/d-valerolactone copolymers, lactide/c-caprolactone copolymers, L-lactide/DL-lactide copolymers, glycolide/L-lactide copolymers (PGA/PLLA), polylactide-co-glycolide; terpolymers of PLA, such as lactide/glycolide/trimethylene carbonate terpolymers, lactide/glycolide/ε-caprolactone terpolymers, PLA/polyethylene oxide copolymers; polydepsipeptides; unsymmetrically 3,6-substituted poly-1,4-dioxane-2,5-diones; polyhydroxyalkanoates; such as polyhydroxybutyrates (PHB); PHB/b-hydroxyvalerate copolymers (PHB/PHV); poly-b-hydroxypropionate (PHPA); poly-p-dioxanone (PDS); poly-d-valerolactone -poly-ε-capralactone, poly(ε-caprolactone-DL-lactide) copolymers; methylmethacrylate-N-vinyl pyrrolidone copolymers; polyesteramides; polyesters of oxalic acid; polydihydropyrans; polyalkyl-2-cyanoacrylates; polyurethanes (PU); polyvinylalcohol (PVA); polypeptides; poly-b-malic acid (PMLA): poly-b-alkanbic acids; polycarbonates; polyorthoesters; polyphosphates; poly(ester anhydrides); and mixtures thereof; and derivatives, copolymers and mixtures thereof.

29. A method of treatment for an orthopedic application in a subject in need of treatment thereof, comprising implanting to the subject the medical implant of claim 1 .

30. The method of treatment of claim 29 , wherein said implanting to the subject comprises performing structural fixation for a load-bearing purpose within the subject.

31. The method of treatment of claim 29 , where said performing structural fixation comprises performing bone fixation.

Assignments (7)
SECURITY INTEREST Recorded Jan 20, 2026
From: OSSIO LTD.
To: MONROE CAPITAL MANAGEMENT ADVISORS, LLC
Reel/Frame 073522/0127 →
RELEASE OF SECURITY INTEREST Recorded Jan 20, 2026
From: COURAGE CREDIT OPPORTUNITIES FUND IV, L.P.
To: OSSIO LTD; OSSIO INC.
Reel/Frame 073525/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2025
From: KRIVORUK, ILYA
To: OSSIO LTD.
Reel/Frame 070242/0788 →
CORRECTIVE ASSIGNMENT TO TO REMOVE THE INVENTOR TAL ZEEVI FROM THIS ASSIGNMENT PREVIOUSLY RECORDED UNDER REEL AND FRAME 059018/0639. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 13, 2025
From: PREISS-BLOOM, ORAHN; LINDNER, TALY PNINA; UCHITEL, ILAN OLEG
To: OSSIO LTD.
Reel/Frame 070226/0343 →
SECURITY INTEREST Recorded Mar 22, 2024
From: OSSIO LTD; OSSIO INC.
To: COURAGE CREDIT OPPORTUNITIES FUND IV, L.P.
Reel/Frame 066873/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2022
From: PREISS-BLOOM, ORAHN; PNINA LINDNER, TALY; OLEG UCHITEL, ILAN; ZEEVI, TAL
To: OSSIO LTD.
Reel/Frame 059018/0639 →
SECURITY INTEREST Recorded Feb 22, 2021
From: OSSIO LTD
To: COURAGE CREDIT OPPORTUNITIES FUND IV, L.P.
Reel/Frame 055354/0037 →
Continuity (2)
Provisional Application 62555070 · Sep 7, 2017
Related Publication 20210369314A1 · Dec 2, 2021
Cited By (2)
US 12,239,766 US 12,383,246